XOMA Corp (XOMA)
25.79
+0.55
(+2.18%)
USD |
NASDAQ |
May 31, 16:00
25.66
-0.13
(-0.50%)
After-Hours: 20:00
XOMA Research and Development Expense (TTM): 0.122M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 0.122M |
December 31, 2023 | 0.143M |
September 30, 2023 | 0.146M |
June 30, 2023 | 0.15M |
March 31, 2023 | 0.151M |
December 31, 2022 | 0.153M |
September 30, 2022 | 0.167M |
June 30, 2022 | 0.168M |
March 31, 2022 | 0.166M |
December 31, 2021 | 0.171M |
September 30, 2021 | 0.165M |
June 30, 2021 | 0.169M |
March 31, 2021 | 0.169M |
December 31, 2020 | 0.17M |
September 30, 2020 | 0.264M |
June 30, 2020 | 0.373M |
March 31, 2020 | 1.059M |
December 31, 2019 | 1.253M |
September 30, 2019 | 1.36M |
June 30, 2019 | 1.854M |
March 31, 2019 | 1.506M |
December 31, 2018 | 1.682M |
September 30, 2018 | 2.105M |
June 30, 2018 | 1.775M |
March 31, 2018 | 4.315M |
Date | Value |
---|---|
December 31, 2017 | 7.876M |
September 30, 2017 | 15.46M |
June 30, 2017 | 23.83M |
March 31, 2017 | 34.62M |
December 31, 2016 | 44.24M |
September 30, 2016 | 49.58M |
June 30, 2016 | 58.47M |
March 31, 2016 | 64.46M |
December 31, 2015 | 70.85M |
September 30, 2015 | 76.63M |
June 30, 2015 | 79.31M |
March 31, 2015 | 79.21M |
December 31, 2014 | 80.75M |
September 30, 2014 | 84.32M |
June 30, 2014 | 82.28M |
March 31, 2014 | 79.76M |
December 31, 2013 | 74.85M |
September 30, 2013 | 67.67M |
June 30, 2013 | 67.88M |
March 31, 2013 | 69.25M |
December 31, 2012 | 68.39M |
September 30, 2012 | 69.28M |
June 30, 2012 | 66.72M |
March 31, 2012 | 66.56M |
December 31, 2011 | 68.14M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
0.122M
Minimum
Mar 2024
1.854M
Maximum
Jun 2019
0.4187M
Average
0.1685M
Median
Research and Development Expense (TTM) Benchmarks
Societal CDMO Inc (DELISTED) | -- |
AbbVie Inc | 7.322B |
AnaptysBio Inc | 134.37M |
Viracta Therapeutics Inc | 35.72M |
NovaBay Pharmaceuticals Inc | 0.061M |